Promising Potential in Perspective Therapeutics' VMT-alpha-NET Program Amid Market Hesitations

TipRanks01:35

Perspective Therapeutics Pursuing Dose Escalation Study in Neuroendocrine Tumors

MT NewswiresNov 21 23:56

Perspective Therapeutics Shares Are Trading Lower. The Company Announced Initial Results From Its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET.

BenzingaNov 21 23:41

Express News | Perspective Therapeutics Inc : Wedbush Cuts Target Price to $11 From $20

BreakingsNov 21 23:23

Dow Jumps Over 100 Points; Nvidia Posts Upbeat Earnings

BenzingaNov 21 23:19

Express News | Amex Halt Add Info Lst 3.400000

BreakingsNov 21 22:43